Mozessohn L, Buckstein R. Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes?. haematol [Internet]. 2026Feb.1 [cited 2026Feb.8];111(2):451-3. Available from: https://haematologica.org/article/view/12147